公开(公告)号：US10017572B2

公开(公告)日：2018-07-10

申请号：US15274603

申请日：2016-09-23

Applicant: Genentech, Inc.

Inventor： Jane L. Grogan ,  Robert J. Johnston ,  Yan Wu ,  Wei-Ching Liang ,  Patrick Lupardus ,  Mahesh Yadav ,  Dhaya Seshasayee ,  Meredith Hazen

IPC: A61K39/395 ,  C07K16/00 ,  C07K16/28 ,  C07K16/30 ,  A61K45/06 ,  A61K38/17 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K38/177 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2878 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/70 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  Y02A50/466

Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.

公开(公告)号：US10047158B2

公开(公告)日：2018-08-14

申请号：US15895741

申请日：2018-02-13

Applicant: Genentech, Inc.

Inventor： Jane L. Grogan ,  Robert J. Johnston ,  Yan Wu ,  Wei-Ching Liang ,  Patrick Lupardus ,  Mahesh Yadav ,  Dhaya Seshasayee ,  Meredith Hazen

IPC: C07K16/00 ,  C07K16/28 ,  A61K38/17 ,  A61K45/06 ,  A61K39/395 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K38/177 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2878 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/70 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  Y02A50/466

Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.

公开(公告)号：US10564165B2

公开(公告)日：2020-02-18

申请号：US14850864

申请日：2015-09-10

Applicant: GENENTECH, INC.

Inventor： Lelia Delamarre ,  Patrick Lupardus ,  Ira Mellman ,  Mahesh Yadav ,  Suchit Jhunjhunwala ,  Jennie Lill

IPC: G01N33/68 ,  C12Q1/6886 ,  A61K39/00 ,  G01N33/569

Abstract: The present disclosure provides methods of identifying a disease-specific immunogenic peptide through a series of selection steps. Immunogenic epitopes identified by methods of the present disclosure are applicable for use in peptide-based immunotherapy, preferably cancer therapy. Furthermore, the methods of the present disclosure may be performed in a high-throughput manner and serve as a means of personalized vaccine development and therapy. Also provided are compositions of immunogenic peptides as well as methods of treatment comprising said compositions.